Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Preferred Stock Liabilities (2017 - 2022)

Historic Preferred Stock Liabilities for Dianthus Therapeutics (DNTH) over the last 2 years, with Q4 2022 value amounting to $118.0 million.

  • Dianthus Therapeutics' Preferred Stock Liabilities changed N/A to $118.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $118.0 million, marking a year-over-year change of. This contributed to the annual value of $118.0 million for FY2022, which is N/A changed from last year.
  • As of Q4 2022, Dianthus Therapeutics' Preferred Stock Liabilities stood at $118.0 million.
  • Dianthus Therapeutics' 5-year Preferred Stock Liabilities high stood at $118.0 million for Q4 2022, and its period low was $118.0 million during Q4 2022.